TY - JOUR T1 - TTF-1 Expression Predicts the Merit of Additional Antiangiogenic Treatment in Non-squamous Non-small Cell Lung Cancer JF - Anticancer Research JO - Anticancer Res SP - 5489 LP - 5495 DO - 10.21873/anticanres.12882 VL - 38 IS - 9 AU - AKIRA TAKEUCHI AU - TETSUYA OGURI AU - YORIKO YAMASHITA AU - KAZUKI SONE AU - SATOSHI FUKUDA AU - OSAMU TAKAKUWA AU - TAKEHIRO UEMURA AU - KEN MAENO AU - KENSUKE FUKUMITSU AU - YOSHIHIRO KANEMITSU AU - HIROTSUGU OHKUBO AU - MASAYA TAKEMURA AU - YUTAKA ITO AU - AKIO NIIMI Y1 - 2018/09/01 UR - http://ar.iiarjournals.org/content/38/9/5489.abstract N2 - Background/Aim: To investigate whether TTF-1 expression predicts a beneficial response of non-squamous non-small-cell lung cancer (NS-NSCLC) patients to bevacizumab. Patients and Methods: We retrospectively screened 118 advanced NS-NSCLC patients who were treated with pemetrexed plus platinum derivatives alone (Bev(−)) or with bevacizumab (Bev(+)), and investigated the relationship between expression of TTF-1 and treatment outcomes. Results: Among the 92 TTF-1-positive patients, clinical outcomes in the Bev(+) group were significantly better than those in the Bev(−) group (response rate, 51.4% vs. 27.3%, p=0.027; median progression-free survival, 216 days vs. 137 days, p=0.012). Overall survival in the Bev(+) group tended to be longer than that in the Bev(−) group. However, the addition of bevacizumab to the standard treatment of 26 TTF-1-negative patients offered no clinical benefit. Conclusion: TTF-1 expression may serve as a predictive marker to identify patients who may benefit from the addition of bevacizumab to platinum doublet therapy. ER -